TREANDA Significantly Improves Clinical Outcomes In Patients With Chronic Lymphocytic Leukemia Compared To Chlorambucil
Cephalon, Inc. (Nasdaq: CEPH) announced that in a pivotal study of treatment-naive patients with chronic lymphocytic leukemia (CLL), those who received TREANDA (bendamustine HCl) had better clinical outcomes compared to patients treated with chlorambucil, an FDA-approved therapy for patients with CLL. TREANDA(R) is a novel investigational chemotherapy that is currently under priority review by the U.S. Food and Drug Administration (FDA). [click link for full article]
More: continued here
Filed under: Lymphoma / Leukemia on December 15th, 2007